+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Relevance of HBe/Anti-HBe System and of DNA Polymerase Activity in Chronic Hepatitis-B Virus Carriers on Haemodialysis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To assess the relevance of HBe/anti-HBe system and DNA polymerase activity in patients on regular dialysis treatment, we prospectively studied 38 patients on haemodialysis, who were chronic carriers of HBs Ag (range 6–66 months), and 26 HBs Ag negative dialysis patients as controls. HBe Ag was present in 74%, DNA polymerase in 60%, and anti-HBe in 13% of HBs Ag positive patients. After a mean follow-up of 23.5 months, only 2 patients, who had been HBe Ag positive, had cleared HBs Ag, and 1 of them had turned to anti-HB S positivity. Among the patients who were still HBs Ag positive, only 1 had lost HBe Ag, without developing anti-HBe. Throughout the study, SGOT and SGPT levels were significantly raised in HB virus carriers as compared to controls. In the HBs Ag positive group, the presence of HBe Ag and/or DNA polymerase characterized a subgroup with the most striking abnormalities in enzyme levels. The causes of death in the HBs Ag positive group were not related to liver disease. Viral replication usually takes place in HB virus carriers on haemodialysis and is associated with biochemical evidence of liver-cell damage. However, the HB virus carrier state, and the underlying liver disease, are not major problems at present in patients on chronic haemodialysis.

          Related collections

          Author and article information

          S. Karger AG
          03 December 2008
          : 29
          : 1-2
          : 44-48
          lstituto di Patologia Medica 1, Università di Bologna; lstituto di Virologia, Università di Milano; Servizio di Nefrologia e Dialisi, Policlinico S. Orsola, e Divisione di Nefrologia e Dialisi, Ospedale Malpighi, Bologna, Italia
          182237 Nephron 1981;29:44–48
          © 1981 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper

          Cardiovascular Medicine, Nephrology

          HBs antigen, Hepatitis, DNA polymerase, Anti-HBe, HBe antigen


          Comment on this article